As summer temperatures soar, children frequently move between air-conditioned indoor spaces and hot outdoor environments—a scenario that can trigger acute bronchitis, characterized by persistent cough, phlegm production, and sometimes wheezing. Parents often ask: “Which medication is most effective for treating pediatric bronchitis?” Amid a wide array of options, Kanglong Pediatric Cough and Asthma Oral Liquid—a traditional Chinese medicine (TCM) formulation specifically developed for children—has emerged as a clinically supported choice, grounded in classical TCM theory and validated through modern multicenter trials.
Acute bronchitis is among the most common respiratory conditions in children. It typically presents with cough, sputum production, and occasionally wheezing, driven primarily by airway inflammation leading to excessive mucus secretion and impaired lung qi dispersion [1]. Importantly, clinicians must distinguish acute bronchitis from bronchiolitis—especially in infants under 2 years, and particularly those under 6 months. According to public health reporting by China National Radio, approximately 70% of bronchiolitis cases are caused by respiratory syncytial virus (RSV). First-line management includes inhaled corticosteroids via nebulization, along with mucolytic agents; antibiotics are generally unnecessary, as the condition is overwhelmingly viral [2]. In contrast, typical acute bronchitis in older infants and young children—particularly when classified in TCM as “wind-heat invading the lung” or “phlegm-heat obstructing the lung”—responds best to therapies that clear heat, disperse lung qi, and resolve phlegm.
From a TCM perspective, children’s lungs are constitutionally “incompletely developed” (a concept known as *fei chang bu zu*), rendering them especially susceptible to external pathogens that rapidly transform into internal heat. Kanglong Pediatric Cough and Asthma Oral Liquid is derived from the classic formula *Ma Xing Shi Gan Tang*, described in Zhang Zhongjing’s *Treatise on Cold Damage Disorders*, and further refined with additional herbs including honeysuckle (*Lonicera japonica*), isatis root (*Isatis tinctoria*), and trichosanthes fruit (*Trichosanthes kirilowii*) [3]. The original formula combines ephedra (*Ephedra sinica*) to promote lung dispersion and relieve wheezing, gypsum (*Gypsum fibrosum*) to clear lung heat, and apricot seed (*Prunus armeniaca*) to descend lung qi and suppress cough. The modified version enhances these actions: honeysuckle and isatis root strengthen heat-clearing and detoxifying effects, while trichosanthes fruit improves phlegm resolution. Collectively, the formula targets the core TCM pathogenesis of “phlegm-heat obstructing the lung,” which aligns closely with the clinical presentation of many pediatric bronchitis cases.
Robust clinical evidence supports its use. A multicenter randomized controlled trial conducted across 12 tertiary hospitals in China evaluated the concentrated formulation of Kanglong Pediatric Cough and Asthma Oral Liquid in children diagnosed with acute bronchitis (wind-heat or phlegm-heat patterns). Results demonstrated significantly higher efficacy rates in resolving cough, expectoration, and auscultatory findings—including diminished rales—compared with control groups. Notably, the concentrated formulation delivers a full therapeutic dose in just 1.25 mL per vial and features improved palatability, enhancing adherence in young patients [4]. A separate study focusing on wheezing bronchitis found that adding this oral liquid to standard Western pharmacotherapy accelerated resolution of cough, wheeze, and fever—and also reduced serum inflammatory cytokine levels while improving objective pulmonary function parameters. This suggests a dual benefit: symptomatic relief coupled with modulation of underlying inflammatory pathways [5].
While medication selection should always be guided by a qualified healthcare provider—and diagnosis must precede treatment—the integration of evidence-informed, pathogenesis-targeted TCM formulations represents a valuable adjunctive strategy in pediatric respiratory care. When weighing therapeutic options for acute bronchitis, clinicians and caregivers may consider agents like Kanglong Pediatric Cough and Asthma Oral Liquid—not solely based on brand recognition, but on their alignment with both classical diagnostic frameworks and contemporary clinical data.